Optic neuritis (ON) is an inflammation that damages your optic nerve. It can cause vision loss and pain when you move your eyes. As the inflammation goes away, your symptoms usually get better.
Subjects with recent onset of unilateral acute optic neuritis were randomised in the trial. Credit: PeopleImages.com – Yuri A/Shutterstock. Oculis Holding has reported that the randomised Phase II ...
Oculis Holding has reported that the randomised Phase II Acute OptiC NeUrITis of DemYelinating Origin (ACUITY) trial of OCS-05, in treating individuals with acute optic neuritis, met the primary e ...
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...
OCS-05, an experimental medication that Oculis is developing to treat acute optic neuritis, a common symptom of multiple sclerosis (MS) that can lead to vision loss, was well tolerated and ...
The trial met safety and efficacy endpoints. OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
Other eye conditions, such as optic neuritis and diplopia, are also known to affect many people with MS. Optic neuritis is a common vision problem related to MS. It’s inflammation of the optic ...
OCS-05 demonstrated safety and neuroprotective benefits in a phase 2 trial for acute optic neuritis, improving visual function and retinal structure. The trial involved 36 patients, with OCS-05 ...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in ...
Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis. Oculis also ...